Neoadjuvant intra-arterial chemotherapy in inflammatory carcinoma of the breast.
From 1982 to 1989, 18 eligible patients (median age 50.5 years, range 30-72 years) with inflammatory breast carcinoma have been treated with neoadjuvant intra-arterial (IA) chemotherapy. The treatment regimen includes IA cisplatin, adriamycin, mytomycin C and thiotepa on Day 1 and intravenous 5-fluorouracil on Days 1 and 2. An objective clinical response rate of 100% (eight complete and 10 partial) has been observed. The median disease-free and overall survivals are 27 months (range 5-85+ months) and 33 months (range 8-85+ months), respectively. With a median follow-up of 21.5 months, six (33.3%) patients remain alive and free of disease and 12 patients have died because of distant metastases. No local recurrences have been observed. Intra-arterial chemotherapy is an attractive technique for the treatment of locally advanced breast carcinoma with mild toxicity and high local control rate.
Bilbao
J I
JI
Department of Radiology, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain.
Rebollo
J
J
Longo
J M
JM
Mansilla
F
F
Muñoz-Galindo
L
L
Vieitez
J M
JM
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008323:Mammary Arteries; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D013852:Thiotepa / Q000008:administration & dosage
D016685:Mitomycin; D004317:Doxorubicin; D013852:Thiotepa; D002945:Cisplatin; D005472:Fluorouracil